BACKGROUND: Hematopoietic stem cell transplantation has become an established procedure worldwide. Severe early and late complications are well described. Little is known about more subtle changes in general health status of very long-term survivors. The study objective was to assess health status of very long-term survivors in comparison with their respective human leukocyte antigen-identical sibling donors. DESIGN AND METHODS: Case matched comparison in a cross-sectional cohort was performed in a tertiary university hospital and referral center for hematopoietic stem cell transplantation. Forty-four pairs of recipients and their respective donors with a very long-term (17.5 years median; 11-26 years range) follow up after allogeneic hematopoietic stem cell transplantation were included. A comparative clinical evaluation and examination of routine clinical chemistry tests was carried out. RESULTS: Recipients more frequently had a lower Karnofsky score (P = 0.05), hypertension (P = 0.015) and dyslipidemia (P = 0.002) but were less likely to be smokers (P = 0.016). Recipients showed systematically lower glomerular filtration rates (P < 0.0001), higher liver function tests (P = 0.0004 for Aspartat-Amino-Transferase) and reduced thyroid function (P = 0.002) despite normal or near normal values, and independent of presence or absence of chronic graft-versus-host disease. Indicators of inflammation were more frequent in recipients (9 of 44) with ongoing chronic graft-versus-host disease as measured by higher C-reactive protein (P = 0.001) and higher von Willebrand factor (P = 0.002). Conclusions Clinically very long-term survivors after an allogeneic hematopoietic stem cell transplantation present more frequently with cardiovascular risk factors and with subtle signs of altered organ function compared to their sibling donors. Even minimal ongoing chronic graft-versus-host disease remains associated with elevated laboratory indicators of inflammation. The clinical significance of these findings needs to be defined.
BACKGROUND: Hematopoietic stem cell transplantation has become an established procedure worldwide. Severe early and late complications are well described. Little is known about more subtle changes in general health status of very long-term survivors. The study objective was to assess health status of very long-term survivors in comparison with their respective human leukocyte antigen-identical sibling donors. DESIGN AND METHODS: Case matched comparison in a cross-sectional cohort was performed in a tertiary university hospital and referral center for hematopoietic stem cell transplantation. Forty-four pairs of recipients and their respective donors with a very long-term (17.5 years median; 11-26 years range) follow up after allogeneic hematopoietic stem cell transplantation were included. A comparative clinical evaluation and examination of routine clinical chemistry tests was carried out. RESULTS: Recipients more frequently had a lower Karnofsky score (P = 0.05), hypertension (P = 0.015) and dyslipidemia (P = 0.002) but were less likely to be smokers (P = 0.016). Recipients showed systematically lower glomerular filtration rates (P < 0.0001), higher liver function tests (P = 0.0004 for Aspartat-Amino-Transferase) and reduced thyroid function (P = 0.002) despite normal or near normal values, and independent of presence or absence of chronic graft-versus-host disease. Indicators of inflammation were more frequent in recipients (9 of 44) with ongoing chronic graft-versus-host disease as measured by higher C-reactive protein (P = 0.001) and higher von Willebrand factor (P = 0.002). Conclusions Clinically very long-term survivors after an allogeneic hematopoietic stem cell transplantation present more frequently with cardiovascular risk factors and with subtle signs of altered organ function compared to their sibling donors. Even minimal ongoing chronic graft-versus-host disease remains associated with elevated laboratory indicators of inflammation. The clinical significance of these findings needs to be defined.
Authors: André Tichelli; Alicia Rovó; Jakob Passweg; Carl Philipp Schwarze; Maria Teresa Van Lint; Mutlu Arat; Gérard Socié Journal: Expert Rev Hematol Date: 2009-10 Impact factor: 2.929
Authors: G Socié; R E Curtis; H J Deeg; K A Sobocinski; A H Filipovich; L B Travis; K M Sullivan; P A Rowlings; D W Kingma; P M Banks; W D Travis; R P Witherspoon; J Sanders; E S Jaffe; M M Horowitz Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: G Socié; J Y Cahn; J Carmelo; J P Vernant; J P Jouet; N Ifrah; N Milpied; M Michallet; B Lioure; J L Pico; F Witz; L Molina; A Fischer; V J Bardou; E Gluckman; J Reiffers Journal: Br J Haematol Date: 1997-06 Impact factor: 6.998
Authors: N Salooja; R M Szydlo; G Socie; B Rio; R Chatterjee; P Ljungman; M T Van Lint; R Powles; G Jackson; M Hinterberger-Fischer; H J Kolb; J F Apperley Journal: Lancet Date: 2001-07-28 Impact factor: 79.321
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee Journal: J Clin Oncol Date: 2011-12-05 Impact factor: 44.544
Authors: Eric J Chow; Kenneth Wong; Stephanie J Lee; Kara L Cushing-Haugen; Mary E D Flowers; Debra L Friedman; Wendy M Leisenring; Paul J Martin; Beth A Mueller; K Scott Baker Journal: Biol Blood Marrow Transplant Date: 2014-02-22 Impact factor: 5.742
Authors: S Joshi; B N Savani; E J Chow; M H Gilleece; J Halter; D A Jacobsohn; J Pidala; G P Quinn; J-Y Cahn; A A Jakubowski; N R Kamani; H M Lazarus; J D Rizzo; H C Schouten; G Socie; P Stratton; M L Sorror; A B Warwick; J R Wingard; A W Loren; N S Majhail Journal: Bone Marrow Transplant Date: 2014-01-13 Impact factor: 5.483
Authors: Saro H Armenian; Wassim Chemaitilly; Marcus Chen; Eric J Chow; Christine N Duncan; Lee W Jones; Michael A Pulsipher; Alan T Remaley; Alicia Rovo; Nina Salooja; Minoo Battiwalla Journal: Biol Blood Marrow Transplant Date: 2016-08-30 Impact factor: 5.742
Authors: Eric J Chow; K Scott Baker; Stephanie J Lee; Mary E D Flowers; Kara L Cushing-Haugen; Yoshihiro Inamoto; Nandita Khera; Wendy M Leisenring; Karen L Syrjala; Paul J Martin Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: Z DeFilipp; R F Duarte; J A Snowden; N S Majhail; D M Greenfield; J L Miranda; M Arat; K S Baker; L J Burns; C N Duncan; M Gilleece; G A Hale; M Hamadani; B K Hamilton; W J Hogan; J W Hsu; Y Inamoto; R T Kamble; M T Lupo-Stanghellini; A K Malone; P McCarthy; M Mohty; M Norkin; P Paplham; M Ramanathan; J M Richart; N Salooja; H C Schouten; H Schoemans; A Seber; A Steinberg; B M Wirk; W A Wood; M Battiwalla; M E D Flowers; B N Savani; B E Shaw Journal: Bone Marrow Transplant Date: 2016-08-22 Impact factor: 5.483
Authors: Priyanka A Pophali; Jeffrey K Klotz; Sawa Ito; Natasha A Jain; Eleftheria Koklanaris; Robert Q Le; Christopher S Hourigan; Bipin N Savani; Kamna Chawla; Sujata Shanbhag; A John Barrett; Minoo Battiwalla Journal: Exp Hematol Date: 2013-10-17 Impact factor: 3.084
Authors: Daniel Wolff; Philipp Y Herzberg; Anne Herrmann; Steven Z Pavletic; Pia Heussner; Friederike Mumm; Christina Höfer; Inken Hilgendorf; Philipp G Hemmati; Ernst Holler; Hildegard Greinix; Sandra A Mitchell Journal: Bone Marrow Transplant Date: 2020-07-31 Impact factor: 5.483
Authors: André Tichelli; Myriam Labopin; Alicia Rovó; Manuela Badoglio; Mutlu Arat; Maria Teresa van Lint; Anita Lawitschka; Carl Philipp Schwarze; Jakob Passweg; Gérard Socié Journal: Cancer Date: 2013-03-19 Impact factor: 6.860